KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
January 19, 2022 16:21 ET
|
KemPharm
KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and...
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
January 12, 2022 07:30 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
January 11, 2022 07:30 ET
|
KemPharm
Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) --...
KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
January 06, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced...
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
December 20, 2021 07:30 ET
|
KemPharm
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced...
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
December 14, 2021 07:30 ET
|
KemPharm
Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects...
KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021
December 13, 2021 16:05 ET
|
KemPharm
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
December 13, 2021 07:30 ET
|
KemPharm
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
November 10, 2021 16:05 ET
|
KemPharm
Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET ...
KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD
November 05, 2021 07:30 ET
|
KemPharm
Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05,...